086450 — DongKook Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Market Cap
KR₩854bn
Enterprise Value
KR₩904bn
Revenue
KR₩927bn

Annual income statement for DongKook Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	594,193	661,647	730,994	812,166	926,884
Cost of Revenue
Gross Profit	350,260	379,826	410,781	447,896	501,598
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	530,974	588,994	664,120	731,746	832,178
Operating Profit	63,219	72,654	66,873	80,420	94,706
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	69,754	68,632	60,838	84,738	92,588
Provision for Income Taxes
Net Income After Taxes	52,916	54,757	48,871	62,336	73,933
Minority Interest
Net Income Before Extraordinary Items
Net Income	50,345	52,896	47,175	61,219	66,020
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	50,345	52,896	47,175	61,219	66,018
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,109	1,172	1,041	1,367	1,408
Dividends per Share